NCT00567086View on ClinicalTrials.gov

Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

October 31, 2006

Study Completion Date

August 31, 2007

Conditions
Migraine
Interventions
DRUG

TEZAMPANEL

Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)

Trial Locations (1)

64109

National Headache Centers, San Francisco

Sponsors
All Listed Sponsors
lead

TorreyPines Therapeutics

INDUSTRY

NCT00567086 - Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine | Biotech Hunter | Biotech Hunter